ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENT
Clinical trials for ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENT explained in plain language.
Never miss a new study
Get alerted when new ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENT trials appear
Sign up with your email to follow new studies for ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug cocktail aims to keep AML in check after transplant
Disease control Not yet recruitingThis study tests a new combination of three chemotherapy drugs (clofarabine, busulfan, and melphalan) given before a stem cell transplant for adults with acute myeloid leukemia (AML) who are in their first remission. The goal is to see if this stronger conditioning regimen can im…
Matched conditions: ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENT
Phase: NA • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 22, 2026 12:03 UTC
-
New blood tests could sharpen CMV monitoring in transplant patients
Knowledge-focused Not yet recruitingThis study looks at whether measuring two new viral markers (CMV-RNA and TTV-DNA) in the blood can give a clearer picture of CMV infection in patients who have had a stem cell transplant and are taking the drug letermovir to prevent CMV. Researchers will track 290 adult transplan…
Matched conditions: ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENT
Sponsor: University of Rome Tor Vergata • Aim: Knowledge-focused
Last updated Jun 22, 2026 11:58 UTC